Mucolysin Skovbær (Acetylcysteine)

Acetylcysteine, the active ingredient in Mucolysin Skovbær, is a mucolytic agent presented as an oral formulation for oral use. It reduces the viscosity of respiratory mucus, facilitating clearance in patients with chronic bronchitis, COPD, cystic fibrosis and other mucus‑producing respiratory conditions, and is commonly employed in therapeutic protocols to improve breathing efficiency and reduce infection risk.

GNH USA supplies Mucolysin Skovbær as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Acetylcysteine is used to thin mucus in several chronic respiratory disease families.

Chronic bronchitis: reduces mucus thickness to improve airway clearance and ease coughing. COPD: lowers sputum viscosity, helping patients expectorate secretions more effectively. Cystic fibrosis: assists in breaking down thick pulmonary secretions, supporting respiratory therapy. Acute respiratory infections: aids in mucus clearance to relieve congestion and facilitate breathing.

Acetylcysteine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Unpleasant taste or bitter sensation

Serious or Rare Side Effects: - Bronchospasm or wheezing - Severe allergic reaction (anaphylaxis) - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When using acetylcysteine, consider the following precautions.

Assess renal function: adjust use in patients with severe renal impairment. Monitor for bronchospasm: observe for wheezing especially in asthmatic individuals. Use with caution in asthma: may provoke bronchial irritation. Avoid in known hypersensitivity: discontinue if allergic signs appear. Pregnancy and lactation: safety not established; weigh benefits against risks. Store at room temperature: keep in the original container, protect from moisture and light.

Acetylcysteine can affect the activity of several concomitant medicines.

Major Interactions (Avoid): - Nitroglycerin: may cause profound hypotension when combined. - Activated charcoal: reduces acetylcysteine absorption if given concurrently.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect; monitor INR. - Certain antibiotics (e.g., penicillins): acetylcysteine may alter urinary excretion. - Inhaled bronchodilators: monitor for additive bronchospasm risk.